YZYinghui Zhong

Yinghui Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yinghui Zhong has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development and characterization of a folic acid delivery system for spinal cord repair

    by Mengxi Yang, Yinghui Zhong

    Traumatic spinal cord injury (SCI) is a debilitating injury that results in physical deficits including loss of motor and sensory function below the injury site. Neuroprotection, inflammation, astroglial-fibrotic scar formation, and axon growth (including regeneration of injured axons and sprouting of spared axons) are the four crucial therapeutic targets for spinal cord repair. While there are strategies to address one or a few these therapeutic targets, combining them to tackle all four targets concurrently poses great technical challenges. Furthermore, the use of multiple therapeutics in a combination approach may potentially interfere with each other's intended therapeutic effects. Folic acid (FA) is an essential vitamin source for normal cellular metabolic function, and it also plays a key role in the development, regeneration, and repair of the CNS. It has been reported to exhibit anti-inflammatory and neuroprotective effects. However, its efficacy in mitigating inflammation and promoting neuroprotection after SCI has not been studied. Our recent studies have, for the first time, shown that FA can directly inhibit both astroglial and fibrotic scar formation. Additionally, studies have shown that FA promoted axon regeneration after SCI via DNA methylation. Therefore, FA has the potential to address all four crucial therapeutic targets after SCI. However, the high concentrations of FA required for achieving these effects cannot be attained by systemic administration. In this study, we developed and characterized a novel biomaterial-based FA delivery system to locally deliver high doses of FA at the injury site, which reduced inflammation, astrocytic-fibrotic scar formation and promoted neuroprotection and functional recovery. Moreover, we investigated the putative mechanisms through which FA may regulate astrocytic-fibrotic scar formation and axonal growth.

  • Enhancing survival and integration of transplanted neural stem/progenitor cells for treating spinal cord injury

    by Nan Hai, Yinghui Zhong

    Traumatic spinal cord injury (SCI) causes partial or complete functional loss below the injury site. Patients with SCI suffer lifelong disability and require continuous physical and medical care. SCI causes neuronal loss and axon degeneration, which disrupts the neural circuitry that controls the functions of spinal cord. In the adult central nervous system (CNS), neurons usually cannot renew themselves to replace the lost neuron population, and achieving long-distance axon growth from the remaining neurons is extremely difficult. Neural stem/progenitor cells (NSPCs) transplantation is a promising therapeutic strategy for replacing lost neurons and establishing neuronal relays, facilitating the reconstruction of damaged neural circuitry. However, poor survival of grafted cells and the formation of astroglial-fibrotic scars remain significant challenges for achieving successful integration and functional recovery. In this study, we aim to address these challenges by utilizing a four-factor cocktail (GNVb, consisting of GSH, NAC, VEGF, and bFGF) to promote NSPC survival and local delivery of hepatocyte growth factor (HGF) to reduce astroglial-fibrotic scar formation. By enhancing NSPC survival with GNVb, we aim to enable the acute transplantation of NSPCs (24 h after SCI), leveraging their immunomodulatory and neuroprotective effects to promote graft-host integration. Concurrently, HGF delivery is expected to mitigate scar formation, further facilitating graft-host integration.

  • Mechanism and efficacy of using polymeric nanoparticles for treating atherosclerosis

    by Yao Zhao, Yinghui Zhong, John Eberth

    Atherosclerosis, a leading cause of cardiovascular disease, is characterized by the accumulation of lipid-laden macrophages (foam cells) in response to modified lipoproteins. As the disease progresses, advanced plaques can restrict or block blood flow, leading to severe cardiovascular complications such as heart attack and stroke. Despite the use of lipid-lowering and antiplatelet therapies, there remains a critical need for direct therapeutic strategies that can reduce plaques while simultaneously addressing the inflammatory and oxidative stress microenvironment. This study explores the potential of dextran sulfate-chitosan nanoparticles (DS-CH NPs) for the treatment of atherosclerosis. We demonstrate that these NPs promote cholesterol efflux from lipid-laden macrophages through the activation of multiple pathways, including ABCA1, SR-B1, and autophagy induction. Additionally, we show that apoA1 and apoE contribute to NP-mediated cholesterol efflux. By encapsulating curcumin within the NPs (CNPs), we enhanced their anti-inflammatory and antioxidant effects. In vivo experiments using an atherosclerotic mouse model confirmed that NPs specifically target atherosclerotic plaques, resulting in reduced plaque size, stabilized plaques, and decreased inflammation, oxidative stress, and hypertriglyceridemia. Safety assessments conducted both in vitro and in vivo have confirmed the safety of NPs and CNPs. These findings suggest that DS-CH NPs and CNPs have potential as novel therapies for atherosclerosis, addressing both cholesterol efflux and the underlying inflammatory and oxidative processes.

  • Hepatocyte Growth Factor Delivery to Injured Cervical Spinal Cord Using an Engineered Biomaterial Protects Respiratory Neural Circuitry and Preserves Functional Diaphragm Innervation

    by Samantha J. Thomas, Biswarup Ghosh, Zhicheng Wang, Mengxi Yang, Jia Nong, Jenna Severa, Megan C. Wright, Yinghui Zhong, Angelo C. Lepore

    A major portion of spinal cord injury (SCI) cases occur in the cervical region, where essential components of the respiratory neural circuitry are located. Phrenic motor neurons (PhMNs) housed at cervical spinal cord level C3–C5 directly innervate the diaphragm, and SCI-induced damage to these cells severely impairs respiratory function. In this study, we tested a biomaterial-based approach aimed at preserving this critical phrenic motor circuitry after cervical SCI by locally delivering hepatocyte growth factor (HGF). HGF is a potent mitogen that promotes survival, proliferation, migration, repair, and regeneration of a number of different cell and tissue types in response to injury. We developed a hydrogel-based HGF delivery system that can be injected into the intrathecal space for local delivery of high levels of HGF without damaging the spinal cord. Implantation of HGF hydrogel after unilateral C5 contusion-type SCI in rats preserved diaphragm function, as assessed by in vivo recordings of both compound muscle action potentials and inspiratory electromyography amplitudes. HGF hydrogel also preserved PhMN innervation of the diaphragm, as assessed by both retrograde PhMN tracing and detailed neuromuscular junction morphological analysis. Furthermore, HGF hydrogel significantly decreased lesion size and degeneration of cervical motor neuron cell bodies, as well as reduced levels surrounding the injury site of scar-associated chondroitin sulfate proteoglycan molecules that limit axon growth capacity. Our findings demonstrate that local biomaterial-based delivery of HGF hydrogel to injured cervical spinal cord is an effective strategy for preserving respiratory circuitry and diaphragm function.


  • Open Access

    Printing GelMA bioinks: a strategy for building in vitro model to study nanoparticle-based minocycline release and cellular protection under oxidative stress

    by Zhouquan Fu, Nan Hai, Yinghui Zhong, Wei Sun

    Owing to its thermoresponsive and photocrosslinking characteristics, gelatin methacryloyl (GelMA)-based biomaterials have gained widespread usage as a novel and promising bioink for three-dimensional bioprinting and diverse biomedical applications. However, the flow behaviors of GelMA during the sol-gel transition, which are dependent on time and temperature, present significant challenges in printing thick scaffolds while maintaining high printability and cell viability. Moreover, the tunable properties and photocrosslinking capabilities of GelMA underscore its potential for localized drug delivery applications. Previous research has demonstrated the successful incorporation of minocycline (MH) into GelMA scaffolds for therapeutic applications. However, achieving a prolonged and sustained release of concentrated MH remains a challenge, primarily due to its small molecular size. The primary aim of this study is to investigate an optimal extrusion printing method for GelMA bioink in extrusion bioprinting, emphasizing its flow behaviors that are influenced by time and temperature. Additionally, this research seeks to explore the potential of GelMA bioink as a carrier for the sustained release of MH, specifically targeting cellular protection against oxidative stress. The material properties of GelMA were assessed and further optimization of the printing process was conducted considering both printability and cell survival. To achieve sustained drug release within GelMA, the study employed a mechanism using metal ion mediation to facilitate the interaction between MH, dextran sulfate (DS), and magnesium, leading to the formation of nanoparticle complexes (MH-DS). Furthermore, a GelMA-based in vitro model was developed in order to investigate the cellular protective properties of MH against oxidative stress. The experimental results revealed that the printability and cell viability of GelMA are significantly influenced by the printing duration, nozzle temperature, and GelMA concentrations. Optimal printing conditions were identified based on a thorough assessment of both printability and cell viability. Scaffolds printed under these optimal conditions exhibited exceptional printability and sustained high cell viability. Notably, it was found that lower GelMA concentrations reduced the initial burst release of MH from the MH-dextran sulfate (MH-DS) complexes, thus favoring more controlled, sustained release profiles. Additionally, MH released under these conditions significantly enhanced fibroblast viability in an in vitro model simulating oxidative stress.


  • Open Access

    Local delivery of AdipoRon from self-assembled microparticles to inhibit myelin lipid uptake and to promote lipid efflux from rat macrophages

    by Robert B Shultz, Nan Hai, Yinghui Zhong

    Objective. Abundant lipid-laden macrophages are found at the injury site after spinal cord injury (SCI). These cells have been suggested to be pro-inflammatory and neurotoxic. AdipoRon, an adiponectin receptor agonist, has been shown to promote myelin lipid efflux from mouse macrophage foam cells. While it is an attractive therapeutic strategy, systemic administration of AdipoRon is likely to exert off-target effects. In addition, the pathophysiology after SCI in mice is different from that in humans, whereas rat and human SCI share similar functional and histological outcomes. In this study, we evaluated the effects of AdipoRon on rat macrophage foam cells and developed a drug delivery system capable of providing sustained local release of AdipoRon to the injured spinal cord. Approach. Rat macrophages were treated with myelin debris to generate an in vitro model of SCI foam cells, and the effects of AdipoRon treatment on myelin uptake and efflux were studied. AdipoRon was then loaded into and released from microparticles made from dextran sulfate and fibrinogen for sustained release. Main results. AdipoRon treatment not only significantly promotes efflux of metabolized myelin lipids, but also inhibits uptake of myelin debris. Myelin debris alone does not appear to be inflammatory, but myelin debris treatment potentiates inflammation when administered along with pro-inflammatory lipopolysaccharide (LPS) and interferon-γ. AdipoRon significantly attenuated myelin lipid-induced potentiation of inflammation. Bioactive AdipoRon can be released in therapeutic doses from microparticles. Significance. These data suggest that AdipoRon is a promising therapeutic capable of reducing lipid accumulation via targeting both myelin lipid uptake and efflux, which potentially addresses chronic inflammation following SCI. Furthermore, we developed microparticle-based drug delivery systems for local delivery of AdipoRon to avoid deleterious side effects. This is the first study to release AdipoRon from drug delivery systems designed to reduce lipid accumulation and inflammation in reactive macrophages after SCI.


  • Modified Agarose Hydrogel Scaffold for Neural Stem Cell Transplantation in Spinal Cord Injuries

    by Maleah Spicer, Fred D. Allen, Yinghui Zhong

    Spinal cord injury (SCI) is a debilitating neurological condition that results from direct trauma to the tissue and causes a loss of motor, sensory, and autonomic functions caudal to or below the site of injury. Globally, SCI has an incidence rate of 250,000 and 500,000 cases with an annual economic impact of $4 billion USD. In the United States, there are between 11,000 and 20,000 new cases of SCI each year. SCIs result from direct trauma to the tissue and cause a partial or complete loss of motor, sensory, and autonomic functions caudal to or below the site of injury. The most frequent SCI are contusion injuries where the lesion site expands over time due to a wave of secondary degeneration resulting in a cystic cavity surrounded by a thin rim of tissue. The secondary injury leads to further neuronal loss, demyelination, and axon transection caused by mechanisms such as bleeding, swelling, and elevated reactive oxygen species (ROS). Since neurons have limited regenerative capacity, the transected axons cannot regenerate in the hostile microenvironment after a SCI. This results in SCI patients having a lifelong disability that requires continuous care. Neural stem/progenitor cells (NSPCs) transplantation is a promising therapeutic strategy to replace lost neurons and rebuild the damaged neural circuitry in SCI. As a result of the large lesion cavity after SCI, a biomaterial scaffold composed of an agarose hydrogel with laminin incorporated is needed as a supporting matrix to promote attachment and survival of the transplanted NSPCs. Agarose is a biocompatible polysaccharide with thermo-reversible properties commonly used as a biomaterial for neural tissue engineering. However, agarose lacks cell adhesion motifs and cannot encourage neuron growth. The incorporation of a cell binding domain can encourage cell attachment and growth. Laminin is a key extracellular matrix regulator of cell adhesion, differentiation, proliferation, and migration in addition to maintaining blood-brain barrier integrity. To develop agarose hydrogels with the ability to have thiol-functionalized laminin attached, it is modified with divinyl sulfone (DVS) via a Michael Addition to the primary hydroxyl groups. This modification allows for a thiolated bioactive molecule, thiolated-laminin, to be attached to the DVS groups on the modified agarose. There are three types of agaroses modified with DVS: SeaPrep (SP), SeaPlaque (SPQ), and SeaKem (SK). The stability, swelling and degradation degree, mechanical properties, and cytocompatibility of the DVS agarose (DVS-Ag) hydrogel at various concentrations were conducted. A seven-day stability study revealed the most stable concentration (w/v) was 1.2% for DVS-SP, 1.0% for DVS-SPQ, and 0.75% for DVS-SK. A seven-day degradation study further demonstrated that the 1.0% DVS-SPQ and 0.75% DVS-SK had less than 30% degradation over the course of 7 days. Additionally, a four-day swelling study showed that 1.0% DVS-SPQ had minimal swelling while 0.75% DVS-SK experienced some degradation prior to swelling. For determining the mechanical properties of 1.0% DVS-SPQ and 0.75% DVS-SK, the hydrogels were compressed to find an elastic modulus of 0.0116 kPa and 0.0107 kPa, respectively. Additionally, the compressive modulus was not statistically significant between 0.75% DVS-SK and 1.0% DVS-SPQ. The modification of agarose with DVS, disorganized the double helical structure and subsequently impacted the stability, degradation, swelling, and compressive modulus. When assessing the amount of thiolated molecules in comparison to non-thiolated molecules released, it confirmed the successful modification of agarose with DVS. Furthermore, it identified that a lower dosage of thiolated-molecules at 100 [mu]g/mL allowed for more thiolated-molecules to adhere to the DVS groups. Moreover, the cytotoxic analysis study indicated that the DVS modification combined with the conjugation of thiolated-laminin, to some degree, was successful in promoting Nph viability and proliferation for 0.75% DVS-SK and 1.0% DVS-SPQ. Overall, 1.0% DVS-SPQ seemed the most promising in promoting the survival of NSPCs as it promoted Nph survival in addition it had lower cycling in swelling degree and degradation. While in some measures this approach was successful, this modification is promising in exploring different thiolated bioactive molecules conjugated to the DVS groups to create a biomaterial scaffold that promotes the survival of NSPCs.

  • Molecular Mediators of Modality-Dependent Axon Facilitated Axon Regeneration Using Novel Tissue Engineered Nerve Grafts

    by Kritika Katiyar, Yinghui Zhong

    Peripheral nerve injury (PNI) is increasingly common with over 200,000 peripheral nerve repairs performed every year in the United States. Common causes of PNI include trauma, tumor excision, and iatrogenic injury. The current gold standard for nerve repair is the autologous nerve graft (autograft) wherein a healthy sensory nerve is taken from another part of the body to repair injured nerve. However, only about 40-50% of patients receiving autograft treatment exhibit adequate functional recovery. This is likely due to the differences in sensory versus motor axon guidance. A major developmental mechanism of axon guidance is axon facilitated axon guidance, where a pioneer axon reaches the end target first, followed by the bolus of growing axons that use the pioneer axon as a guide; this is also seen in vitro when motor neurons and sensory neurons are co-cultured. Current nerve repair strategies do not take into consideration modality dependent axon regeneration. To address this, we have utilized the technique of axon stretch-growth to develop tissue engineered nerve grafts (TENGs) consisting of long, aligned axon tracts. We have previously reported the efficacy of TENGs in bridging critical nerve gap lengths. These first generation TENGs were comprised of pure sensory stretch grown axons. Here we expand this technology to include motor and mixed motor-sensory stretch grown axons to better suit different nerve types. Motor and mixed motor-sensory TENGs were fabricated by implementing the technique of forced neuronal aggregation and culturing these motor aggregates in custom-built mechanobioreactors. These stretch grown constructs were then used as a testbed to determine key molecular mediators of axon guidance by analyzing expression levels of specific cell adhesion molecules (CAMs) in sensory and motor TENGs over time and the effect of stretch growth on CAM expression. Lastly, sensory, motor, and mixed motor-sensory TENGs were transplanted into a rat sciatic nerve injury model to determine the regenerative efficacy of these modality specific constructs. Electrophysiological and nerve and muscle morphometry assessments confirmed that inclusion of motor axons into the constructs improved functional regeneration outcomes.

  • Development and Characterization of Multifunctional Nanoparticles for Prevention and Treatment of Atherosclerosis

    by Jia Nong, Kenneth A. Barbee, Yinghui Zhong

    Atherosclerosis is the leading cause of cardiovascular disease, which can result in the development of myocardial infarctions, heart failure, strokes, and death. It is caused by signaling interactions between inflamed or dysfunctional endothelial, activated monocytes and lipid-laden macrophages (foam cells) in response to the accumulated modified lipoprotein within the vessel walls, and results in plaque development and chronic inflammation. Foam cells play a pivotal role in the occurrence and development of atherosclerosis by contributing to lipid accumulation, necrotic core expansion, plaque formation and further inflammatory amplification at the plaque sites. The management of atherosclerosis is challenged by high plasma concentration of circulating low-density lipoprotein (LDL) cholesterol, foam cell formation and inflammatory cascade. Current treatments tend to have very limited effect with several inherent drawbacks. In addition, they lack the ability to simultaneously address multiple mechanisms contributing to atherosclerosis. In this work, we harnessed nanotechnology to develop polymeric nanoparticles using dextran sulfate and chitosan. We found that these nanoparticles could bind to LDL and inhibit oxLDL internalization via scavenger receptor A and CD36. In addition, our study shows that they induced cholesterol efflux from foam cells possibly via the upregulation of Apolipoprotein A1 gene expression and acting as HDL particles to receive effluxed cholesterol. In vivo study using Apolipoprotein E -/- mouse model confirmed the safety of our nanoparticles, their ability to lower blood LDL cholesterol level without significantly effect on HDL level, and their efficacy in reducing atherosclerotic plaque size. Further, these nanoparticles can be loaded with curcumin, an anti-oxidative and anti-inflammatory drug. Our study shows that the curcumin-loaded nanoparticles can effectively inhibit foam cell formation and attenuate inflammation. Thus, this work highlights the promise of our nanoparticles to ameliorate or reverse the atherosclerosis progress.